Nelistotug
Highest phase reached
Phase 2
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Antibody
- Drug name
- Nelistotug
- Gamma1 heavy chain Homo sapiens (1-452) [VH(Homo sapiens IGHV1-69*01 (95.9%) -(IGHD)-IGHJ1*01 (90.9%) L123>T (117), CDR-IMGT [8.8.15](26-33.51-58.97-111)) (1-122) -Homo sapiens IGHG1*01 (100%), G1m17,1 CH1 K120, CH3 D12, L14 (CH1 K120 (219) (123-220), hinge 1-15 (221-235), CH2 (236-345), CH3 D12 (361), L14 (363) (346-450), CHS (451-452)) (123-452)], (225-213')-disulfide with kappa light chain Homo sapiens (1'-213') [V-KAPPA (Homo sapiens IGKV1-39*01 (95.7%) -IGKJ4*01 (91.7%), CDR-IMGT [6.3.8] (27-32.50-52.89-96)) (1'-106') -Homo sapiens IGKC*01 (100%), Km3, A45.1 (152), V101 (190) (107'-213')]; dimer (231-231'':234-234'')-bisdisulfide, produced in Chinese Hamster Ovary (CHO) Cell line, glycoform alfa
- gamma1 heavy chain homo sapiens 1 452 vh homo sapiens ighv1 69 01 95 9 ighd ighj1 01 90 9 l123 t 117 cdr imgt 8 8 15 26 33 51 58 97 111 1 122 homo sapiens ighg1 01 100 g1m17 1 ch1 k120 ch3 d12 l14 ch1 k120 219 123 220 hinge 1 15 221 235 ch2 236 345 ch3 d12 361 l14 363 346 450 chs 451 452 123 452 225 213 disulfide with kappa light chain homo sapiens 1 213 v kappa homo sapiens igkv1 39 01 95 7 igkj4 01 91 7 cdr imgt 6 3 8 27 32 50 52 89 96 1 106 homo sapiens igkc 01 100 km3 a45 1 152 v101 190 107 213 dimer 231 231 234 234 bisdisulfide produced in chinese hamster ovary cho cell line glycoform alfa
- gsk 6097608
- Gsk 6097608
- GSK-6097608
- gsk6097608
- Gsk6097608
- GSK6097608
- immunoglobulin g1 anti human cd96 antigen human monoclonal gsk6097608 γ1 chain disulfide with human monoclonal gsk6097608 κ chain dimer
- Immunoglobulin G1, anti-(human CD96 antigen) (human monoclonal GSK6097608 γ1-chain), disulfide with human monoclonal GSK6097608 κ-chain, dimer
- nelistotug
- Nelistotug
- Nelistotug (immunoglobulin G1-kappa, anti-[Homo sapiens CD96 (T cell activation increased late expression, TACTILE, T-cell surface protein tactile)], Homo sapiens monoclonal antibody)
- nelistotug [INN]
- NELISTOTUG [USAN]
- Nelistotug [WHO-DD]
- nelistotug immunoglobulin g1 kappa anti homo sapiens cd96 t cell activation increased late expression tactile t cell surface protein tactile homo sapiens monoclonal antibody
- nelistotug inn
- nelistotug usan
- nelistotug who dd
- CAS registry numbers
- 2645437-82-5
- ChEMBL ID
- CHEMBL5315022
- FDA ingredient codes (UNII)
- 7MCC43O1YB
- First in class
- No
- Orphan designation
- No
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition
- Head and Neck Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005950
- Subject identifier
- D006258
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0010150
- Highest recorded phase
- 2
- NCT03739710
- NCT04446351
- NCT05565378
- NCT06062420
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Heavy chain
- Type
- Protein
- Sequence
- QVQLVQSGAEVKKPGSSVKVSCKASGGTEVEYAISWVRQAPGQGLEWMGGITPAFGTAQYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGAGYYGDKDPMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
- Component
- Disulfide bridges
- Sequence
- 22-96 $ 22''-96'' $ 23'-88' $ 23'''-88''' $ 133'-193' $ 133'''-193''' $ 149-205 $ 149''-205'' $ 225-213'' $ 22''-213'''' $ 231-231'' $ 234-234'' $ 266-326 $ 266''-326'' $ 372-430 $ 372''-430''
- Component
- Light chain
- Type
- Protein
- Sequence
- DIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQVLHTITEGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
- Component
- Glycosylation sites (N)
- Sequence
- 302 $ 302''
Related records
Trials (6)
- A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
- A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
- First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
- Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)
- Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3
- Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors
In development for (3)
- Head and neck neoplasm Phase 2
- Neoplasm Phase 2
- Non-small cell lung carcinoma Phase 2